Opportunity Alert – AC-160105-085 – QUINTILES-06
Date Sourced: March 22, 2016
Category: Customer Opportunity
Status: Active Discussion
Potential (High-Moderate-Low): Moderate
Add to SFA (Y/N): TBD
Client Action Required (Y/N): No
Opportunity:
Quintiles works with many of the leading biopharmaceutical and other life
science companies. Their core clinical solutions and services that include
project management and clinical monitoring functions for conducting
multi-site Phase II-IV trials. This is a strategic pursuit given that
Quintiles has helped develop or commercialize 90% of the best-selling
pharma products, all of Top 30 Oncology products, and all of Top 30 CNS
products; and operates in 81 countries supporting 1,000+ oncology studies,
375+ pediatric studies, and 230+ rare disease studies.
Website:
www.quintiles.com
Summary of Activities/Tasks:
1. March 22, 1016 – Met with Tom Pike, Quintiles CEO at the Clinical Trials
Collaboration (CTC) conference in Cambridge, MA. Tom expressed his thoughts
on what trial innovation is needed to move the industry forward; and for
CROs to enhance their value proposition. I raised the issue of the
importance of real-time med adherence and remote subject monitoring
technology. More than just providing additional data points – effective med
adherence technology can directly improve trial outcomes by providing
actionable insights into subject adherence, compound toxicity and protocol
compliance.
2. March 30, 2016 – Sent Tom the CleverCap short deck. Still awaiting
feedback and comments.
3. April 7, 2016 – Coordinating schedules with Alan Metz, Quintiles SVP of
Partnerships and Alliances to explore CleverCap opportunities. Alan is the
head of all 14 Q Therapeutic COEs.
Forward Statements and Guidance:
Looking to meet in Durham headquarters late April. Efforts are underway to
pull in as many senior management as possible for onsite presentation and
follow-on discussion. Potential contacts include: Stewart Rosen (Medical),
Bernadette Tosti (Site & patient networks), and Chris Giles (BD).
End.
Return to Listing
COMMENT FORM.
Comments